GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Current Ratio

Clarity Pharmaceuticals (ASX:CU6) Current Ratio : 11.76 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Clarity Pharmaceuticals's current ratio for the quarter that ended in Dec. 2023 was 11.76.

Clarity Pharmaceuticals has a current ratio of 11.76. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Clarity Pharmaceuticals's Current Ratio or its related term are showing as below:

ASX:CU6' s Current Ratio Range Over the Past 10 Years
Min: 10.17   Med: 12.51   Max: 58.83
Current: 11.76

During the past 2 years, Clarity Pharmaceuticals's highest Current Ratio was 58.83. The lowest was 10.17. And the median was 12.51.

ASX:CU6's Current Ratio is ranked better than
83.3% of 1545 companies
in the Biotechnology industry
Industry Median: 3.78 vs ASX:CU6: 11.76

Clarity Pharmaceuticals Current Ratio Historical Data

The historical data trend for Clarity Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Current Ratio Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
Current Ratio
13.26 10.17

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Current Ratio Get a 7-Day Free Trial 40.43 13.26 11.45 10.17 11.76

Competitive Comparison of Clarity Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, Clarity Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarity Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Current Ratio falls into.



Clarity Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Clarity Pharmaceuticals's Current Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Current Ratio (A: Jun. 2023 )=Total Current Assets (A: Jun. 2023 )/Total Current Liabilities (A: Jun. 2023 )
=76.678/7.542
=10.17

Clarity Pharmaceuticals's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=57.564/4.894
=11.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarity Pharmaceuticals  (ASX:CU6) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Clarity Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (ASX:CU6) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines